Items Tagged ‘Chronic Lymphoblastic Leukemia’

July 11th, 2016

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

By

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Chronic lymphocytic leukemia is the most common form of adult leukemia. The American […]

View full entry

Tags: 2016, asco, Bruton’s tyrosine kinase, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CLL, early-stage, ibrutinib, imbruvica, Leukemia, News


February 29th, 2016

Arzerra® Approved as Maintenance Therapy for Advanced CLL

By

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not received prior therapy, or whose CLL has stopped responding to prior therapies. CLL is a type of cancer […]

View full entry

Tags: arzerra, B-cells, biologic agent, CD-20, Chronic Lymphoblastic Leukemia, chronic lymphocytic, CLL, fda, Leukemia, News, ofatumumab, PROLONG


August 25th, 2014

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia

By

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. The lymph system includes the spleen, thymus, tonsils, bone marrow, lymph nodes, and circulating immune […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, CLL, Leukemia, News, zydelig


December 16th, 2013

Gazyva/Chlorambucil Improves Outcomes in Older CLL Patients with Other Health Problems

By

Among older people with chronic lymphocytic leukemia (CLL) and other health problems, initial treatment with Gazyva® (obinutuzumab) and chlorambucil was more effective than treatment with Rituxan® (rituximab) and chlorambucil. These results were presented at the 2013 Annual Meeting of the American Society of Hematology. CLL is a slow-growing blood and bone marrow disease. It is […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Leukemia, News


June 3rd, 2013

Ibrutinib Active In Untreated, Relapsed and Unresponsive CLL

By

The drug ibrutinib was well tolerated and highly effective in patients with untreated, relapsed and unresponsive chronic lymphocytic leukemia—leading to large reductions in tumor burden, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2013, held in Washington, D.C., April 6-10. Chronic lymphocytic leukemia (CLL) is […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Leukemia, News


October 11th, 2012

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma

By

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published in Mayo Clinic Proceedings. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes, which are the cells that are responsible for […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Melanoma, News, Non-Hodgkin's Lymphoma, Screening/Prevention Melanoma


February 16th, 2012

Combination of Campath and Fludarabine Provides Benefit in CLL

By

Among people with previously treated, relapsed or refractory chronic lymphocytic leukemia (CLL), treatment with a combination of Campath® (alemtuzumab) and fludarabine results in better outcomes than treatment with fludarabine alone. These results were published in Lancet Oncology. Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. The American Cancer Society estimates that […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Leukemia, News


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


February 1st, 2010

Arzerra, Fludara, and Cytoxan Promising for Previously Untreated CLL

By

The combination of Arzerra™ (ofatumumab), Fludara® (fludarabine), and Cytoxan® (cyclophosphamide) shows promising effectiveness in the initial treatment of chronic lymphocytic leukemia (CLL). These results were presented at the 2009 annual meeting of the American Society of Hematology. Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. The American Cancer Society estimates that […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Leukemia, News


January 5th, 2010

Treanda® and Rituxan® Effective Initial Therapy for CLL

By

According to the results of a Phase II clinical trial, the combination of Treanda® (bendamustine) and Rituxan® (rituximab) is effective and safe for the initial treatment of patients with advanced chronic lymphocytic leukemia (CLL). These results were presented at the 2009 annual meeting of the American Society of Hematology. Chronic lymphocytic leukemia is the most […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Leukemia, News


December 11th, 2008

Treanda® and Rituxan® Effective for Relapsed CLL

By

Treanda® and Rituxan® Effective for Relapsed CLL In a Phase II clinical trial, the combination of Treanda® (bendamustine)®and Rituxan® (rituximab)®produced promising results among patients with relapsed chronic lymphocytic leukemia (CLL). These results were presented at the 50th Annual Meeting of the American Society of Hematology. CLL is a disease characterized by high numbers of circulating […]

View full entry

Tags: Chronic Lymphoblastic Leukemia